Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TSC1
REST API REST API
Homo sapiens
TSC1 is differentially expressed in 216 experiments: 102 organism parts: lung, bone marrow, ... (100 more);, 144 disease states: normal, glioblastoma, ... (142 more);, 54 cell types 294 cell lines 25 compound treatments and 59 other conditions.
Synonyms hamartin, TSC, LAM, KIAA0243
Orthologs Tsc1 (Rattus norvegicus)   TSC1 (Gallus gallus)   Tsc1 (Mus musculus)   tsc1b (Danio rerio)   A6QQZ6_BOVIN (Bos taurus)   ENSCING00000004555 (Ciona intestinalis)   tsc1a (Danio rerio)   Tsc1 (Drosophila melanogaster)   tsc1 (Xenopus laevis)   tsc1 (Xenopus laevis)   TSC1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, embryo development, protein stabilization, protein binding, cardiac muscle cell differentiation, actin filament, cytoplasm, cell cortex, regulation of cell-matrix adhesion, negative regulation of cell proliferation, protein complex, membrane, protein N-terminus binding, chaperone binding, cell cycle arrest, regulation of translation, regulation of protein kinase activity, insulin receptor signaling pathway, potassium ion transport, membrane fraction, regulation of phosphoprotein phosphatase activity, synapse organization, microsome, cell-matrix adhesion, activation of Rho GTPase activity, lamellipodium, negative regulation of TOR signaling cascade, growth cone, nervous system development, regulation of actin cytoskeleton organization, cell projection organization, negative regulation of translation, GTPase activating protein binding, negative regulation of cell size, TSC1-TSC2 complex, positive regulation of focal adhesion assembly, myelination, neural tube closure, kidney development, cerebral cortex development, regulation of focal adhesion assembly, GTPase regulator activity, cytoskeletal part, response to insulin stimulus, hippocampus development, regulation of stress fiber assembly, rRNA export from nucleus, protein heterooligomerization
InterPro Term Hamartin
UniProt Accession Q92574, Q86WV8, B7Z897, B7Z604, F5H701
Gene-Disease Assocation TUBEROUS SCLEROSIS 1; TSC1, FOCAL CORTICAL DYSPLASIA OF TAYLOR; FCDT, LYMPHANGIOLEIOMYOMATOSIS; LAM
Search EB-eye ENSG00000165699
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (33 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
DU145
2
E-GEOD-17482, E-GEOD-20089
MDA-MB-231
2
E-GEOD-5823, E-TABM-420
SNU16
2
E-MTAB-37, E-GEOD-15460
BT474
1
2
E-MEXP-440, E-MTAB-62, E-MTAB-37
SNU5
1
E-MTAB-37
288 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-19397, E-MEXP-750, E-GEOD-20677, ... (34 experiments)

Factor Value U/D Experiments
centroblast
2
E-GEOD-15271, E-TABM-702
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
leydig cell
1
E-MTAB-25
epithelioid malignant mesothelioma (MM)
1
E-GEOD-21750
M1 macrophage
1
E-GEOD-5099
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
48 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-22529, E-GEOD-1869, E-MEXP-2069, E-MEXP-1121, ... (45 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MEXP-567, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-62, E-MEXP-231
inflammatory myopathy
1
E-MTAB-62
childhood acute myeloid leukemia
1
E-GEOD-2191
nephrosclerosis
1
E-GEOD-20602
monoclonal gammopathy of unknown significance
1
E-MTAB-62
138 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, E-GEOD-3720, E-GEOD-5099, ... (17 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-20719, E-MEXP-1958, E-GEOD-412, E-GEOD-7307, E-GEOD-4600, ... (6 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
potassium dichromate
1
E-GEOD-6907
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
sevoflurane
1
E-GEOD-4386
cigarette smoke
1
1
E-TABM-127
19 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-GEOD-2666

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-20847, E-MEXP-2340, E-GEOD-4006, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-21750, E-GEOD-22593, E-TABM-601

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-TABM-127, E-GEOD-20504, ... (6 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-MEXP-1290, E-GEOD-19519, ... (22 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-4600

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-4922

Processing time: 0.289 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM